|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-12-31
|
|
pubmed:abstractText |
Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
127-31
|
|
pubmed:dateRevised |
2009-1-14
|
|
pubmed:meshHeading |
pubmed-meshheading:18165647-Adult,
pubmed-meshheading:18165647-Aged,
pubmed-meshheading:18165647-Aged, 80 and over,
pubmed-meshheading:18165647-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18165647-Benzenesulfonates,
pubmed-meshheading:18165647-Carcinoma, Papillary,
pubmed-meshheading:18165647-Carcinoma, Renal Cell,
pubmed-meshheading:18165647-Female,
pubmed-meshheading:18165647-Humans,
pubmed-meshheading:18165647-Indoles,
pubmed-meshheading:18165647-Kidney Neoplasms,
pubmed-meshheading:18165647-Male,
pubmed-meshheading:18165647-Middle Aged,
pubmed-meshheading:18165647-Prognosis,
pubmed-meshheading:18165647-Pyridines,
pubmed-meshheading:18165647-Pyrroles,
pubmed-meshheading:18165647-Survival Rate,
pubmed-meshheading:18165647-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
|
|
pubmed:affiliation |
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. Toni_Choueiri@dfci.harvard.edu
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
